加巴喷丁与普瑞巴林在双相障碍、焦虑状态和失眠中的应用:系统综述、Meta分析与理论依据
该系统综述与Meta分析纳入55项双盲随机对照试验和15项开放标签研究,评估加巴喷丁与普瑞巴林在双相障碍、焦虑和失眠中的证据。焦虑谱系中加巴喷丁类药物优于安慰剂(SMD范围-2.25至-0.25),术前焦虑中普瑞巴林(SMD -0.55,95%CI -0.92至-0.18)和加巴喷丁(SMD -0.92,95%CI -1.32至-0.52)均优于安慰剂;双相障碍和失眠证据有限,结果不确定。
要点
- 焦虑谱系中加巴喷丁类药物较安慰剂有一致但非普遍的效果,SMD范围-2.25至-0.25。
- 术前焦虑中普瑞巴林SMD -0.55(95%CI -0.92至-0.18),加巴喷丁SMD -0.92(95%CI -1.32至-0.52),均优于安慰剂。
- 双相障碍仅4项加巴喷丁双盲RCT,无普瑞巴林双盲RCT,因异质性未行定量合成;失眠结果不确定。
核心结论
- 作者认为,加巴喷丁类药物在焦虑状态中有中等强度证据,但在双相障碍和失眠中证据极少,用于这些疾病时应有充分理由。
- 该推荐不因靶向电压门控钙通道的药理学和遗传学理论依据而改变。
研究设计与样本
- 系统综述与Meta分析,纳入55项双盲随机对照试验和15项开放标签研究。
- 双相障碍方面,鉴定出4项调查加巴喷丁的双盲随机对照试验,无调查普瑞巴林的双盲随机对照试验。
- 因研究人群、设计和结局指标的异质性,未对双相障碍进行定量合成。
主要发现
- 焦虑谱系中,加巴喷丁类药物与安慰剂比较可见一致但非普遍的效果,标准化均数差(SMD)范围在-2.25至-0.25之间。
- 术前焦虑中,普瑞巴林(SMD -0.55,95%CI -0.92至-0.18)和加巴喷丁(SMD -0.92,95%CI -1.32至-0.52)均比安慰剂更有效。
- 失眠方面,结果不确定。
临床怎么用
- 作者认为,加巴喷丁类药物在焦虑状态中有中等强度证据,但在双相障碍和失眠中证据极少,用于这些疾病时应有充分理由。
局限性
- 双相障碍因研究人群、设计和结局指标的异质性,未能进行定量合成。
- 双相障碍仅鉴定出4项加巴喷丁双盲随机对照试验,无普瑞巴林双盲随机对照试验。
- 失眠方面结果不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gabapentinoids, gabapentin, and pregabalin, target the α2δ subunits of voltage-gated calcium channels. Initially licensed for pain and seizures, they have become widely prescribed drugs. Many of these uses are off-label for psychiatric indications, and there is increasing concern about their safety, so it is particularly important to have good evidence to justify this usage. We conducted a systematic review and meta-analysis of the evidence for three of their common psychiatric uses: bipolar disorder, anxiety, and insomnia. Fifty-five double-blind randomised controlled trials (RCTs) and 15 open-label studies were identified. For bipolar disorder, four double-blind RCTs investigating gabapentin, and no double-blind RCTs investigating pregabalin, were identified. A quantitative synthesis could not be performed due to heterogeneity in the study population, design and outcome measures. Across the anxiety spectrum, a consistent but not universal effect in favour of gabapentinoids compared to placebo was seen (standardised mean difference [SMD] ranging between -2.25 and -0.25). Notably, pregabalin (SMD -0.55, 95% CI -0.92 to -0.18) and gabapentin (SMD -0.92, 95% CI -1.32 to -0.52) were more effective than placebo in reducing preoperative anxiety. In insomnia, results were inconclusive. We conclude that there is moderate evidence of the efficacy of gabapentinoids in anxiety states, but minimal evidence in bipolar disorder and insomnia and they should be used for these disorders only with strong justification. This recommendation applies despite the attractive pharmacological and genetic rationale for targeting voltage-gated calcium channels.
引用
- Hong JSW, Atkinson LZ, Al-Juffali N, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Mol Psychiatry. 2021. PMID: 34819636. doi:10.1038/s41380-021-01386-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。